eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Companyâ€™s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
08/06/26	0.000200 $	0.00%	978
05/06/26	0.000200 $	0.00%	2,640

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 18:32:15 08/06/2026 +04			5-day change	1st Jan Change
0.000200 ^USD	0.00%		0.00%	-

11/09/24	Tyra Biosciences Names Doug Warner Chief Medical Officer	MT
08/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index	CI

Market Cap	940 815.73 751.92 704.56 1.32K 90.01K 1.34K 8.97K 3.47K 43.39K 3.53K 3.45K 151K	P/E Ratio 2022	-0.78x	P/E Ratio 2023	-0.71x
Enterprise Value	2.18M 1.89M 1.74M 1.63M 3.05M 208M 3.11M 20.76M 8.04M 100M 8.17M 7.99M 349M	EV / Sales 2022	3,344,920x	EV / Sales 2023	-
Free-Float	99.75%	Yield 2022 *	-	Yield 2023	-

11/09/24	Tyra Biosciences Names Doug Warner Chief Medical Officer	MT
08/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index	CI
02/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index	CI
25/06/24	Sector Update: Health Care Stocks Rise in Late Afternoon Trading	MT
24/06/24	Top Midday Decliners	MT
24/06/24	EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives	MT
24/06/24	EFFECTOR Therapeutics, Inc. Announces Cessation of Michael Byrnes, Chief Financial Officer	CI
24/06/24	Effector Therapeutics, Inc. Terminates Its Employees in Connection with the Planned Wind Down of the Company?s Operations	CI
24/06/24	Effector Therapeutics, Inc. Announces Director Resignations	CI
24/06/24	EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as CEO	CI
24/06/24	EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board	CI
20/05/24	EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer	CI
10/05/24	EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

24/08/23	HC Wainwright Starts eFFECTOR Therapeutics With Buy Rating, $5 Price Target	MT
26/05/23	Stifel Upgrades eFFECTOR Therapeutics to Buy From Hold, Adjusts Price Target to $7 From $1.30	MT
10/05/23	Credit Suisse Trims eFFECTOR Therapeutics' Price Target to $5.50 From $7, Keeps Outperform Rating	MT
09/03/23	Credit Suisse Adjusts eFFECTOR Therapeutics' Price Target to $7 From $8, Keeps Outperform Rating	MT
09/01/23	JMP Securities Trims Price Target on eFFECTOR Therapeutics to $1 From $2, Maintains Market Outperform Rating	MT

eFFECTOR Therapeutics, Inc. Stock

Stocks

EFTR

US28202V2079

Biotechnology & Medical Research

Valuation: eFFECTOR Therapeutics, Inc.

Chart: eFFECTOR Therapeutics, Inc.

Latest news : eFFECTOR Therapeutics, Inc.

Analysts' recommendations: eFFECTOR Therapeutics, Inc.

Press Releases: eFFECTOR Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: eFFECTOR Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

13/08/24	FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer	AQ
26/06/24	EFFECTOR Therapeutics : Accelaration/Increase of Financial Obligation Form 8 K	PU
24/06/24	EFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq	AQ
04/04/24	EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	AQ
05/02/24	EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	AQ

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0.02
3 years	0		31.5
5 years	0		1,010.5
10 years	0		1,010.5

Date	Insider	Type	Main position	Quantity	% Market Cap.
13/06/24	Kristen Harrington-Smith	Free	Director	800	0.0170%
13/06/24	Caroline Loewy	Free	Director	800	0.0170%
13/06/24	Brian Gallagher	Free	Chairman	800	0.0170%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EFFECTOR THERAPEUTICS, INC.	0.00%	0.00%	0.00%	-100.00%	940
ARGENX SE	+0.21%	+1.51%	+53.74%	+110.16%	55.58B
WUXI APPTEC CO., LTD.	+0.03%	+0.33%	+49.22%	+43.94%	43.47B
BIONTECH SE	+3.93%	-0.06%	-15.10%	-18.04%	22.64B
INSMED INCORPORATED	+5.27%	-7.82%	-1.29%	+388.48%	20.96B
WUXI BIOLOGICS (CAYMAN) INC.	+3.81%	-5.07%	+12.00%	-29.52%	15.79B
GENMAB A/S	-0.36%	+0.06%	+8.63%	-40.30%	15.3B
EXELIXIS, INC.	+1.75%	+1.92%	+29.13%	+178.65%	13.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.27%	+5.54%	+14.25%	-	11.74B
PHARMAESSENTIA CORPORATION	-5.27%	-0.43%	+87.77%	+208.02%	10.96B
Average	+1.47%	-0.38%	+23.84%	+82.38%	20.99B
Weighted average by Cap.	+1.42%	+0.76%	+31.45%	+97.74%

	2022	2023
Net sales	3.55 3.08 2.84 2.66 4.98 340.2 5.08 33.9 13.13 163.99 13.34 13.05 570.19	-
Net income	-22.66M -19.67M -18.13M -16.99M -31.74M -2.17B -32.4M -216M -83.73M -1.05B -85.08M -83.25M -3.64B	-35.81M -31.08M -28.65M -26.84M -50.15M -3.43B -51.2M -342M -132M -1.65B -134M -132M -5.75B
Net Debt	-6.03M -5.23M -4.82M -4.52M -8.44M -577M -8.62M -57.53M -22.27M -278M -22.63M -22.15M -968M	2.18M 1.89M 1.74M 1.63M 3.05M 208M 3.11M 20.75M 8.04M 100M 8.16M 7.99M 349M